PetMed Express (PETS) Panoramica del titolo
PetMed Express, Inc. insieme alle sue consociate, opera come farmacia per animali domestici negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
PETS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di PetMed Express, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$1.79 |
| Massimo di 52 settimane | US$4.10 |
| Minimo di 52 settimane | US$1.57 |
| Beta | 0.77 |
| Variazione di 1 mese | -19.73% |
| Variazione a 3 mesi | -19.73% |
| Variazione di 1 anno | -46.73% |
| Variazione a 3 anni | -87.28% |
| Variazione a 5 anni | -94.74% |
| Variazione dall'IPO | 43.20% |
Notizie e aggiornamenti recenti
PETS: Rural King Partnership And Board Review Will Support Future Upside
Analysts have adjusted their price target for PetMed Express to reflect updated views on revenue growth, profit margins, and a future P/E of 12.41. This has led to a revised valuation that aligns more closely with their current earnings expectations for the stock.PETS: Rural King White Label Pharmacy Will Support Future Margin Upside
Analysts have kept their price target on PetMed Express effectively unchanged at about $2.15, reflecting only very small tweaks to inputs such as discount rate, expected revenue trend, profit margin and future P/E assumptions. What's in the News PetMed Express announced a partnership with Rural King to launch a pet pharmacy service across Rural King retail stores and digital platforms, offering prescription medications, preventatives and other pet health products.PetMed Express: High-Risk Turnaround, Hidden Assets, Activism
Summary PetMed Express’ current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support - although continued operating losses will reduce that support. Ultimately, the investment case depends less on asset values and more on on whether management can stabilize revenue and translate operational improvements into earnings. PETS is more of an asset-backed special situation than an operational turnaround. Read the full article on Seeking AlphaRecent updates
PETS: Rural King Partnership And Board Review Will Support Future Upside
Analysts have adjusted their price target for PetMed Express to reflect updated views on revenue growth, profit margins, and a future P/E of 12.41. This has led to a revised valuation that aligns more closely with their current earnings expectations for the stock.PETS: Rural King White Label Pharmacy Will Support Future Margin Upside
Analysts have kept their price target on PetMed Express effectively unchanged at about $2.15, reflecting only very small tweaks to inputs such as discount rate, expected revenue trend, profit margin and future P/E assumptions. What's in the News PetMed Express announced a partnership with Rural King to launch a pet pharmacy service across Rural King retail stores and digital platforms, offering prescription medications, preventatives and other pet health products.PetMed Express: High-Risk Turnaround, Hidden Assets, Activism
Summary PetMed Express’ current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support - although continued operating losses will reduce that support. Ultimately, the investment case depends less on asset values and more on on whether management can stabilize revenue and translate operational improvements into earnings. PETS is more of an asset-backed special situation than an operational turnaround. Read the full article on Seeking AlphaPETS: Rural King Partnership Will Shape Future Margins And Earnings Outlook
Analysts have slightly reduced their price target on PetMed Express, attributing the change to a marginally lower discount rate and a modest increase in the assumed future P/E multiple as the main factors behind the revised outlook. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King’s retail stores and digital platforms, focusing on prescription medications, preventatives and broader pet health products (Key Developments).PETS: Rural King Partnership Will Shape Future Margins And Earnings Multiple
Analysts have trimmed their price target on PetMed Express to reflect a fair value update from $3.00 to $2.15 as they incorporate more moderate expectations for revenue contraction, profit margins, and a higher future P/E multiple into their models. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King retail stores and digital platforms, expanding access to prescription medications, preventatives and pet health products for Rural King customers (Key Developments).Getting In Cheap On PetMed Express, Inc. (NASDAQ:PETS) Is Unlikely
It's not a stretch to say that PetMed Express, Inc.'s ( NASDAQ:PETS ) price-to-sales (or "P/S") ratio of 0.3x right now...Some Confidence Is Lacking In PetMed Express, Inc. (NASDAQ:PETS) As Shares Slide 26%
To the annoyance of some shareholders, PetMed Express, Inc. ( NASDAQ:PETS ) shares are down a considerable 26% in the...
Cost Cuts And Digital Upgrades Will Strain Future Margins
Optimism regarding savings from PetCareRx integration could jeopardize future profitability if anticipated savings do not materialize.PetMed Express: Dip Or Rip, A Buy After Earnings
Summary PetMed Express stock could surge or sink after this week's quarterly earnings release, but don't read too much into this near-term event. A disappointing earnings release won't necessarily shatter the bull case, and could, in fact, push this stock back down to "back up the truck" price levels. Conversely, even if PETS rallies on strong results, this may not capture all of the potential long-term upside. Even if it takes time to take shape, improvements in PetMed's operating performance could ultimately send the stock back to prices north of $15 per share. Read the full article on Seeking AlphaWe Think PetMed Express (NASDAQ:PETS) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Some PetMed Express, Inc. (NASDAQ:PETS) Shareholders Look For Exit As Shares Take 28% Pounding
PetMed Express, Inc. ( NASDAQ:PETS ) shares have retraced a considerable 28% in the last month, reversing a fair amount...PetMed Express: Why (And Why Not) The Rebound Could Continue
Summary PetMed Express (PETS) surged 35.8% on Nov. 7, following the online pet pharmacy's latest quarterly earnings release. Despite the massive post-earnings surge, further upside may lie ahead, if the turnaround continues. PetMed's management team is implementing a strategy change, not just cost-cutting measures, to continue improving the company's fiscal performance. Although many risks and uncertainties remain, given the outsized impact further improvements could have on the PETS stock price, at the very least add it to your watchlist. Read the full article on Seeking AlphaOptimistic Investors Push PetMed Express, Inc. (NASDAQ:PETS) Shares Up 28% But Growth Is Lacking
PetMed Express, Inc. ( NASDAQ:PETS ) shares have had a really impressive month, gaining 28% after a shaky period...PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
There's been a notable change in appetite for PetMed Express, Inc. ( NASDAQ:PETS ) shares in the week since its...PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates
PetMed Express, Inc. ( NASDAQ:PETS ) last week reported its latest annual results, which makes it a good time for...PetMed Express, Inc.'s (NASDAQ:PETS) Intrinsic Value Is Potentially 69% Above Its Share Price
Key Insights Using the Dividend Discount Model, PetMed Express fair value estimate is US$7.95 Current share price of...A Look At The Fair Value Of PetMed Express, Inc. (NASDAQ:PETS)
Key Insights PetMed Express' estimated fair value is US$11.85 based on 2 Stage Free Cash Flow to Equity Current share...PetMed Express (NASDAQ:PETS) Is Paying Out A Dividend Of $0.30
The board of PetMed Express, Inc. ( NASDAQ:PETS ) has announced that it will pay a dividend of $0.30 per share on the...Rendimenti per gli azionisti
| PETS | US Specialty Retail | US Mercato | |
|---|---|---|---|
| 7D | 2.3% | 3.3% | -2.5% |
| 1Y | -46.7% | 8.7% | 20.1% |
Ritorno vs Industria: PETS ha avuto una performance inferiore rispetto al US Specialty Retail che ha registrato un rendimento 8.7 % nell'ultimo anno.
Rendimento vs Mercato: PETS ha avuto una performance inferiore al mercato US che ha registrato un rendimento 20.1 % nell'ultimo anno.
Volatilità dei prezzi
| PETS volatility | |
|---|---|
| PETS Average Weekly Movement | 7.0% |
| Specialty Retail Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: PETS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di PETS è diminuita da 14% a 7% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1996 | 189 | Leslie C. Campbell | www.1800petmeds.com |
PetMed Express, Inc. opera, insieme alle sue controllate, come farmacia per animali domestici negli Stati Uniti. L'azienda commercializza farmaci per animali da compagnia con e senza ricetta, prodotti per la salute e altre forniture per cani, gatti e cavalli. Offre farmaci e forniture senza ricetta, come prodotti per il controllo di pulci e zecche, prodotti per la cura delle ossa e delle articolazioni, vitamine, leccornie, integratori alimentari, prodotti per l'igiene e forniture domestiche per animali domestici; e farmaci con ricetta, tra cui prodotti per la prevenzione dei vermi cardiaci, per le pulci e le zecche, per l'artrite, per la dermatite, per la tiroide, per il diabete, per il dolore, per il cuore e per la pressione sanguigna e altri farmaci speciali, oltre a sostituti generici.
PetMed Express, Inc. Riepilogo dei fondamenti
| PETS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$37.64m |
| Utili (TTM) | -US$57.29m |
| Ricavi(TTM) | US$179.02m |
PETS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| PETS Conto economico (TTM) | |
|---|---|
| Ricavi | US$179.02m |
| Costo del fatturato | US$128.81m |
| Profitto lordo | US$50.22m |
| Altre spese | US$107.50m |
| Utili | -US$57.29m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -2.72 |
| Margine lordo | 28.05% |
| Margine di profitto netto | -32.00% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato PETS nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/25 03:53 |
| Prezzo dell'azione a fine giornata | 2026/06/24 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
PetMed Express, Inc. è coperta da 15 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Erin Wilson Wright | BofA Global Research |
| Kristine Koerber | Citizens JMP Securities, LLC |
| David Westenberg | CL King & Associates, Inc. |